Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after ...

Follicular lymphoma is the second most common form of non-Hodgkin lymphoma (NHL), and is ... adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... form of non-Hodgkin lymphoma (NHL).

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.